Tag:

Pfizer

Latest Headlines

Latest Headlines

Pfizer lifts guidance as Prevnar, Ibrance trigger Q2 beats

Analysts expected Pfizer's Established Products division to keep suffering on generic competition to Celebrex and Zyvox in Q2. But they didn't foresee new-launch Ibrance and key vaccine Prevnar 13 picking up as much slack as they did, helping the pharma giant surpass both top- and bottom-line estimates and prompting it to up its guidance.

Pfizer claims more R&D space in Cambridge, MA, settling into a biotech hotbed

Pfizer, among the horde of drugmakers looking to Cambridge, MA, for innovation, is expanding its outpost in the city's Kendall Square neighborhood, planning to plant about 1,000 workers in what has become biotech's fastest-growing neighborhood.

Pfizer talks up 'comprehensive' vaccines business

Though it can boast its ownership of the world's bestselling vaccine in Prevnar, Pfizer is not stopping there. On Tuesday, the New York City-based pharma unveiled details of its effort to build out its vaccines business by researching a range of conditions from birth until old age.

Yale scientists highlight a promising eczema study for Pfizer's Xeljanz

Yale scientists successfully tried out Pfizer's rheumatoid arthritis drug Xeljanz (tofacitinib) on a small group of people suffering from severe, treatment-resistant eczema, highlighting its added promise after the drug also demonstrated its potential in fighting two other skin conditions.

Report: U.K. academic R&D alliances are expensive but worth it

A report commissioned by the United Kingdom government has found data to corroborate a widely held belief: R&D collaborations with British universities are expensive. Yet with such institutions performing world-class science--and tax breaks and funding schemes offsetting the upfront costs--Big Pharma is lining up to strike deals. Just ask Pfizer.

GSK, Pfizer, AstraZeneca collaborations tilt U.K. academics to Big Pharma

Just days ago, GlaxoSmithKline signed the first big deal with the Francis Crick Institute. And now a high-profile examination of the state of play of partnering in academic research circles, the Dowling Report, says Glaxo is the single largest collaborator with academia in the U.K., for any industry.

Pfizer, SV give GSK spinout money to expand into schizophrenia research

Autifony Therapeutics has returned to its investors for £8 million ($12 million) to fund a broadening of its R&D ambitions. The company, which spun out of GlaxoSmithKline with an age-related hearing loss program in 2011, is now going after schizophrenia.

Expect vaccines market to swell to $40B by 2020: Tufts CSDD

Two recently-published market analyses paint a picture of a competitive but growing vaccines field through 2020, with the newest report from Tufts University stating the industry is on track to post $40 billion in annual sales in 5 years.

Pfizer announces it will shutter India plant, echoing same news from Sandoz

Pfizer will be closing a plant in India later this year. The announcement comes less than a week after Novartis announced that its Sandoz generics unit would close a plant in India at the end of 2016.

Pfizer closing India plant, laying off workers

Pfizer intends a close one of its plants in India, a facility that has sat mostly idle for two years. But it is not as if Pfizer will be short on manufacturing capacity in the country. As soon as it completes its $15 billion deal to buy Hospira, it will get that company's massive manufacturing network there, including a brand-spanking-new plant in Vizag.